Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD 237 dose-ranging placebo-controlled COPD study with open-label tiotropium
2004-001806-29Phase 2Completed
- Sponsor
- Arakis
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Arakis. Primary endpoint: Trough FEV1 at Day 28 compared to Baseline. Started Jul 2005; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2004-001806-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001806-29.